The Latest Biology News And Medical NewsBiology News 2Health News 2Biology News 3Health News 3
HOME >> MEDICINE >> NEWS
Miller, Schuman receive ARVO/Pfizer Ophthalmics award

Rockville, Md. -- The Association for Research in Vision and Ophthalmology (ARVO) announced today that Joan W. Miller, MD, and Joel S. Schuman, MD, have been selected to receive the 2006 ARVO/Pfizer Ophthalmics Translational Research Award during ARVO's Annual Meeting to be held in Fort Lauderdale, Fla., in May 2006.

The ARVO/Pfizer Award is presented to honor excellence in research and fundamental scientific discoveries, concepts and novel technologies, leading to clinical evidence of diagnosis, prevention, or amelioration of the pathological eye and/or an understanding of the normal vision processes. The award is presented to two researchers annually.

Miller was selected for her research in non-human primates, and subsequent translation to humans, leading to the development of photodynamic therapy of neovascular age-related macular degeneration. She is the Henry Willard Williams Professor and Chair of Ophthalmology at Harvard Medical School. In addition, Miller is Chief of Ophthalmology at the Massachusetts Eye and Ear Infirmary in Boston. She is a past recipient of the American Academy of Ophthalmology Achievement Award, the Alcon Research Institute Award, and the Retina Research Award of the Club Jules Gonin. Miller is the Chairman of the Executive Committee of the Harvard Medical School Department of Ophthalmology.

Schuman was chosen for his role as a key researcher in the development of optical coherence tomography that is widely used clinically in the diagnosis and management of glaucoma and retinal diseases. He is Eye and Ear Foundation Professor and Chairman of Ophthalmology at the University of Pittsburgh School of Medicine. In 2002, Schuman received the Alcon Research Institute Award of Excellence and, the following year, the American Academy of Ophthalmology's Senior Achievement Award. He serves on numerous editorial boards for vision-related journals including Investigative Ophthalmology & Visual Science and Glaucoma Tod
'"/>

Contact: Elinore Tibbetts
etibbetts@arvo.org
240-221-2923
Association for Research in Vision and Ophthalmology
24-Oct-2005


Page: 1 2

Related medicine news :

1. Indiana University Imaging Center receives $6M grant for kidney research
2. FPG receives $8 million for autism research
3. USC and Childrens Hospital Los Angeles both receive grants for stem cell facilities
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. Boston University School of Medicine faculty member receives honorary degree from alma mater
6. UCLA Stroke Center receives American Stroke Associations Initial Achievement Award
7. San Francisco VA researcher receives top Veterans Affairs award
8. RAND study finds women with heart disease and diabetes less likely to receive proper care
9. Ronald W. Busuttil receives American Surgical Associations highest honor
10. Menzies School of Health Research receives $5.3 million in Federal Budget
11. Who receives a kidney transplant first?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Miller Schuman receive ARVO Pfizer Ophthalmics award

(Date:11/23/2009)...action might ease the problem, researchers say , ... who bottle up their anger over unfair treatment a...h study indicates. , Men who consistently faile...a fellow worker or supervisor were more than twice...disease as those who vented their anger, claims a ...
(Date:11/23/2009).../PRNewswire-FirstCall/--InfoLogix,Inc.(Nasdaq: IFL...solutionsforthehealthcareandcommercialindustries,a...edServicesatSiemensHealthServices,hasjoinedInfoLog..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...icHealthcareServicesforInfoLogix,Mr.Waywillberespo...
(Date:11/23/2009)...PRNewswire-USNewswire/--TheAmericanSocietyofHemato...ng,education,andmediacompany,arelaunching"Exploret...dtosparkinterestinthefieldsofscienceandmedicine,in...itiesinhematology. ,, "Manyhematologistsmayreme...ficent,whichmadelearningaboutbloodreallyfun,"state...
(Date:11/23/2009)... patients and survivors treated with chemotherapy ...me chronic conditions, hindering patients, ability...University of Rochester Medical Center. , A stud...leep troubles at nearly three times the rate of th...nt in younger patients and those with lung and bre...
(Date:11/23/2009)...are professionals enjoy a pay raise for a job well... for health care performance may actually backfire...performance ratings for 25 medical groups across C...nch of a statewide pay-for-performance program in ...productivity. , Reporting in the December edi...
Breaking Medicine News(10 mins):Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3
(Date:11/23/2009)...,, EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRe...(TM): Feraheme report,thesecondinamulti-phasesyn...G,snewIVironproduct,Feraheme,throughthefirstsixmon...esquantitativeinformationfrom50uniqueNephrologists...sassesstrialanduseofFeraheme,obstaclestouse,reason...
(Date:11/23/2009)...,, WALTHAM,Mass.,Nov.23/PRNewswire/--Proteon...alstudyofitsleadproduct,PRT-201,inend-stagerenaldi...usgraft(AVG)creation.TheAVGstudyrepresentsProteon,...eviouslyannouncingtheinitiationofaPhase1/2studyofP...ousfistula(AVF)creationearlierthisyear.Proteonalso...
(Date:11/23/2009)...,, SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswir...uncedthatDr.TedW.LoveandDr.DavidC.U,Prichardhaveag...etionoftheproposedmergerbetweenAnesivaandArcionThe...ldervotescheduledtotakeplaceatthepreviouslyannounc...nDecember3,2009at9:00a.m.PSTat400OysterPoint,Suite...
Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Study examines dietary influences of liver disease 50559 1Study examines dietary influences of liver disease 50559 2Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement 12874 1Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement 12874 2Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement 12874 3TeamHealth Recognized by National Quality Agency 50555 1TeamHealth Recognized by National Quality Agency 50555 2TeamHealth Recognized by National Quality Agency 50555 3
Other News:
...DIEGO, April 20, 2007 A policy paper and principl...ity to comment on performance ratings that they be... American College of Physicians (ACP) at its annua...eloping a Fair Process Through Which Physicians Pa...
...AM, N.C. -- Medical professionals conducting clini...inancial conflicts of interest before they talk to...at is one of the main conclusions of a new survey ... and Johns Hopkins University. Their study found t...
... unique collaborative paper in PLoS Medicine, a fo...marketing reveal the tactics used by drug reps to ... reps increase drug sales by influencing physician...iendship," say the authors, Adriane Fugh-Berman (G...
...st half of sales visits by pharmaceutical company ...apentin led to doctors stating that they intended ...mmend it to colleagues, according to an analysis o...the visits.... Nearly 40 percent of the visits inv...
health news:Physicians should be able to review performance rates before release 2health news:Physicians should be able to review performance rates before release 3health news:Physicians should be able to review performance rates before release 4health news:Clinical trial coordinators need more financial conflict-of-interest training 2health news:Clinical trial coordinators need more financial conflict-of-interest training 3health news:Drug reps use friendship to influence doctors 2health news:Drug company sales visits influenced doctors, study finds 2health news:Drug company sales visits influenced doctors, study finds 3
...NJ, January 31, 2000) -- Bristol-Myers Squibb anno...cation (NDA) with the U.S. Food and Drug Administr...so known as ddI. The new capsules contain enteric...ential medicine in VIDEX from degrading until it h...
...calling for all children to be properly restrained...Centre Ltd. are looking at ways to increase flight...ren. They estimate that an average of 5.6 million ...year. *..Roger Hardy, Director of the Cranfield Im...
...;o phenomenon -- the warming of the equatorial Pac...- has been linked to outbreaks of dengue, malaria,...kins School of Public Health, A.B. Prisma, and the...und that the 1997-1998 El Niño season incre...
... Wiesel Among Signatories of The Charter of Paris ... ... ... ... ... Paris, 4 Feb., 2000 - Today m...patient advocacy, cancer research organizations an...itment to the global eradication of cancer by sign...
health news:Bristol-Meyers Squibb submits NDA for new formulation of once daily videx(R)(didanosine) 2health news:Bristol-Meyers Squibb submits NDA for new formulation of once daily videx(R)(didanosine) 3health news:Cranfield pushes for greater child flight safety 2health news:Cancer summit launches global commitment to improve cancer care, research and treatment 2